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Abstract: Oxidative stress and inflammation are two sides of the same coin that are intricately combined to elicit a 
chronic pathophysiological stress state, especially as seen in cardiovascular remodelling. In this review, we argue that ad-
ministration of deoxycorticosterone acetate (DOCA) and sodium chloride to uninephrectomised rats, defined as DOCA-
salt hypertensive rats, provides a reliable animal model of oxidative and inflammatory stress in the cardiovascular system. 
The supporting evidence includes pathophysiological and biochemical changes together with pharmacological responses 
to synthetic and natural compounds that lower the concentrations of reactive free radical species and that curtail inflam-
matory responses in the cardiovascular system.  
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INTRODUCTION 
  Cardiovascular remodelling is the outcome of chronic 
pathophysiological stress in the cardiovascular system [1]. 
The changes include hypertension, hypertrophy and fibrosis, 
ultimately leading to an enlarged and more rigid myocar-
dium, together with electrical conduction changes in the 
heart and smooth muscle and endothelial dysfunction in the 
vasculature [1, 2]. The aetiology of cardiovascular structural 
remodelling includes complex biochemical pathways associ-
ated with an inflammatory reaction and the generation of 
reactive free radicals [3]. Oxidative stress and inflammation 
are two sides of the same coin that are intricately combined 
to elicit a chronic pathophysiological stress state [3]. Under-
standing these pathways should allow improved interven-
tions in the clinical management of the consequences of car-
diovascular remodelling. 
  The cellular damage induced by superoxide and other 
reactive oxygen-containing free radicals is defined as oxida-
tive stress [4]. Superoxide (O2
), hydroxyl (OH
), and per-
oxynitrite (ONOO
) are reactive molecules characterized by 
the presence of unpaired electrons [4, 5]. Reactive oxygen 
species such as superoxide are produced in the cells of the 
body by enzymes including xanthine oxidase, cyclooxy-
genases, lipoxygenases, myeloperoxidases, cytochrome P450 
monooxygenase, uncoupled nitric oxide synthase, heme 
oxygenases, peroxidases, NADPH oxidases and the enzymes 
of the mitochondrial electron transport chain [5, 6]. Superox-
ide can rapidly react with nitric oxide (NO) to form per-
oxynitrite or convert to hydrogen peroxide to form hydroxyl 
radicals [6]. Superoxide plays important roles in the func-
tioning of normal cells, including cell signalling pathways 
and may also recruit and activate immune cells, such 
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as neutrophils as part of the microvascular inflammatory 
response to pathogens [6, 7]. To maintain physiological con-
centrations, superoxide is removed by enzymes including 
superoxide dismutases, glutathione peroxidases, catalase and 
thioredoxin reductase as well as by reaction with small 
molecule antioxidants including glutathione, ascorbic acid 
and other dietary components [4, 5]. Increased superoxide 
concentrations, either by increased production or decreased 
removal, result in cellular damage [4]. 
  Inflammation is described as the short-term primary re-
sponse of the body, crucial for tissue repair, involving many 
complex signals in distinct cells and organ systems to deal 
with injuries [8]. This response turns pathological when acti-
vated for longer periods. Various bioactive mediators such as 
cytokines and chemokines orchestrate the inflammatory re-
sponse in association with inflammatory cells [8]. An in-
creased population of activated tissue inflammatory cells 
producing reactive free radicals can perpetuate oxidative 
stress [9]. To fuel this process, inflammatory cells such as 
leukocytes increase expression and activity of pro-oxidant 
enzymes including myeloperoxidase and NADPH oxidases 
thereby aiding in the generation of excess reactive oxygen 
free radicals [4, 6]. Further, redox regulation of inflamma-
tory signalling occurs at several levels, including direct ef-
fects of oxidants, modulation by antioxidants, alterations in 
the redox equilibrium (for example, thioredoxin and the ratio 
of reduced:oxidized glutathione) and activation of oxidant- 
and redox-sensitive transcription cofactors such as NFB 
and AP-1 [10]. 
OXIDATIVE STRESS, INFLAMMATION AND CAR-
DIOVASCULAR REMODELLING 
  In cardiovascular remodelling, both oxidative stress me-
diated by reactive free radical species and inflammation fol-
lowing infiltration of immune-inflammatory cells are 
strongly implicated in inducing hypertension, hypertrophy, 
fibrosis, conduction abnormalities and endothelial dysfunc-292    Current Cardiology Reviews, 2010, Vol. 6, No. 4  Iyer et al. 
tion in animal models and humans leading to heart failure [3, 
6, 11-13]. Oxidative stress probably promotes inflammation 
[14] and conversely, inflammation-induced damage pro-
motes oxidative stress [15, 16]. The contributions of oxida-
tive and inflammatory stress towards the pathology and pro-
gression of cardiovascular structural remodelling have been 
difficult to separate. 
  Rats have been used for scientific research for about 150 
years; the commonly used Wistar rat strain was developed in 
1906. Rat models of cardiovascular disease, especially hy-
pertension and heart failure [17], have been extensively stud-
ied to provide insights into the pathogenesis and progression 
of cardiovascular disease and to investigate possible thera-
peutic interventions. This suggests that the interactions be-
tween oxidative and inflammatory stress and cardiovascular 
disease may be unravelled with studies on a suitable rat 
model that mimics both inflammatory and oxidative stress 
responses. This review will present the arguments that the 
uninephrectomised Wistar rat treated with deoxycorticoster-
one acetate (DOCA) and sodium chloride, referred to as 
DOCA-salt hypertensive rats, reliably models the relation-
ship between oxidative stress, inflammation and cardiovas-
cular disease.  
DOCA-SALT HYPERTENSIVE RAT MODEL 
  The administration of a synthetic mineralocorticoid de-
rivative, DOCA, in combination with salt loading in the diet 
to young adult Wistar rats following surgical removal of one 
kidney induces hypertension with cardiovascular remodel-
ling characteristic of human volume-overload induced hyper-
tension, especially hypertrophy, fibrosis, conduction abnor-
malities and endothelial dysfunction [18-24]. Similar cardio-
vascular remodelling occurs in patients with hypertension 
and heart failure [3] but these patients are usually not young, 
nor on a high salt diet, nor taking salt-retaining compounds 
nor functioning with a single kidney. Many different ex-
perimental protocols have been reported to induce DOCA-
salt hypertension in the literature including subcutaneous 
implantation of DOCA pellets [25, 26]. In our studies, 8-9 
week old male Wistar rats weighing around 300-330g are 
anaesthetised with an intraperitoneal injection of Zoletil (ti-
letamine (25 mg/kg) and zolazepam (25 mg/kg)) together 
with xylazine (10 mg/kg Rompun) for uninephrectomy; a 
lateral abdominal incision is made to provide access to the 
kidney, and the left renal vessels and ureter are ligated. The 
left kidney is removed and weighed, and the incision site is 
sutured with sterile suture needles. The sutured site is also 
clipped with wound healing clips as a precautionary measure 
as well as to aid faster healing of the incision site. After 
uninephrectomy, rats are randomized into two groups: 
uninephrectomy with no further treatment, and uninephrec-
tomy given 1% NaCl in the drinking water with subcutane-
ous injections of DOCA (25 mg in 0.4 mL of dimethylfor-
mamide every fourth day, DOCA-salt rats). Experiments are 
generally performed 28 days after surgery [27-37]. 
  DOCA-salt rats mimic most of the changes seen in 
chronic cardiovascular remodelling in humans including 
hypertension, hypertrophy, fibrosis, electrical conduction 
abnormalities and vascular hypertrophy and dysfunction. 
Cardiac hypertrophy is pronounced in the DOCA-salt hearts 
and seen in both the left and right ventricles. Echocardio-
graphic studies have shown a thickening of the left ventricu-
lar posterior wall without any change in the left ventricular 
chamber diameter suggesting concentric hypertrophy [36]. 
Cardiac fibrosis and scar tissue formation develops in both 
the left and right ventricles with increased expression of col-
lagen I and III mRNA [21, 24, 38-41] leading to excessive 
perivascular and interstitial collagen deposition [21, 24]. The 
increased scar tissue formation is accompanied by a severe 
inflammatory insult seen as an increased extravasation of 
leukocytes into the ventricular tissue. These changes are ac-
companied by electrical remodelling as an increase in action 
potential duration at 20%, 50% and 90% of repolarisation 
[36]. Functional changes include a decrease in E/A flow ra-
tio, cardiac output, contractile and relaxation measurements 
(+dP/dT, -dP/dT) and an increase in diastolic stiffness in the 
DOCA-salt hearts [36]. Vascular hypertrophy can be severe 
in small and large arteries from DOCA-salt hypertensive 
rats, with a prominent thickening of the media [42]. Smooth 
muscle and endothelial dysfunction is seen as decreased re-
sponses to sodium nitroprusside and acetylcholine respec-
tively, in isolated blood vessels [43-45].  
MECHANISMS OF CARDIOVASCULAR REMOD-
ELLING IN DOCA-SALT HYPERTENSION 
  Clinical studies have shown primary aldosteronism or a 
decrease in renin to aldosterone ratio to be a significant 
cause of hypertension [16, 46, 47]. The DOCA-salt hyper-
tensive rat model shows a markedly depressed renin-
angiotensin system and thus has been regarded as an angio-
tensin-independent model with decreased circulating plasma 
renin concentrations [47]. Increased concentrations of aldos-
terone lead to increased reabsorption of sodium ions and 
water from epithelial cells in the distal nephron of the kid-
ney, thereby influencing blood pressure levels [47]. Aldos-
terone binds to the mineralocorticoid receptor, a member of 
the nuclear receptor family of ligand-dependent transcription 
factors, thereby also regulating gene transcription. This min-
eralocorticoid receptor is expressed in other sites, such as 
vascular smooth muscle cells, cardiac fibroblasts and the 
brain, thus modifying the classic view that aldosterone acts 
exclusively on transport epithelia [47]. Increased aldosterone 
concentrations may activate oxidative stress through an 
upregulated NADPH oxidase in the DOCA-salt model [48]. 
The NADPH oxidases (NOX) are a family of 7 members 
with distinct distributions, consisting of a catalytic subunit, a 
p22phox subunit, regulatory subunits, activator proteins and 
a small G-protein. NOX 2, 4 and 5 are found in endothelial 
cells with NOX 1 and 4 in vascular smooth muscle cells and 
NOX 2 and 4 in adventitial fibroblasts [49]. Aldosterone 
induces superoxide generation via mineralocorticoid recep-
tor-mediated activation of NADPH oxidase and Rac1 in en-
dothelial cells, thereby contributing to the development of 
aldosterone-induced vascular injury [48]. NADPH oxidase 
amplifies the reactive oxygen species formation in the myo-
cardium as its activity increases during heart failure which in 
turn induces NO synthase uncoupling and xanthine oxidase 
activity [4]. NADPH oxidase is the major contributor to re-
active oxygen species generation in various cardiovascular 
disease models and its effect is directly related to the in-
creased protein concentrations. The expression of NADPH Cardiovascular Remodelling in DOCA-Salt hypertensive Rats  Current Cardiology Reviews, 2010, Vol. 6, No. 4    293 
oxidase and its protein subunits such as Rac1 and p67phox 
were increased during the progression of cardiovascular dis-
eases and heart failure [50]. NADPH oxidase activation re-
leasing reactive oxygen species contributed to vascular endo-
thelial dysfunction, apoptosis and inflammation [50]. 
NADPH oxidase-induced superoxides in sympathetic gan-
glia were also responsible for increased neurogenic vasocon-
striction [51]. Over-expression of p47phox and gp91phox 
and reduced expression of intracellular superoxide dismutase 
have also been reported with increased salt loading [52]. 
These findings suggest that NADPH oxidase is increased and 
is responsible for increased superoxide production and pos-
sibly contributes to the increased blood pressure in the 
DOCA-salt hypertensive rat [53]. Thus, the administration of 
the synthetic mineralocorticoid, DOCA, in combination with 
a high salt intake and uninephrectomy mimics the responses 
of hyperaldosteronism-induced hypertension. 
  Although elevated blood pressure may probably be a 
major effector of cardiac hypertrophy in the DOCA-salt hy-
pertensive rats, neurohumoral factors such as endothelin, 
vasopressin and sympathetic nerves may play an important 
independent role in regulating cardiovascular remodelling in 
these rats [54]. In addition, endothelin-1 concentrations were 
elevated in the DOCA-salt rat, which also increased NADPH 
oxidase-induced superoxide production, also contributing to 
the endothelin-1-induced vasoconstriction [55]. The endo-
thelin system plays an important role in the pathogenesis of 
DOCA-salt hypertension and associated remodelling [39, 40, 
56, 57]. Endothelin-1 gene and prepro-endothelin-1 mRNA 
and immunoreactive endothelin-1 concentrations in mesen-
teric resistance arteries and the aorta were increased in 
DOCA-salt rats [58, 59]. Further evidence for a role of endo-
thelin in the DOCA-salt model is provided by administration 
of an endothelin antagonist, which not only lowered blood 
pressure, but also induced reversal of hypertrophic arterial 
remodelling [60], left ventricular fibrosis and inflammation 
[39, 40] and renal and cardiac hypertrophy [40].  
  Chronic stimulation of vasopressin V2 receptor, probably 
by excessive Na
+ retention, increased basal blood pressure 
and worsened the development of DOCA-salt hypertension, 
organ damage and mortality [61]. Collagen III was elevated 
from day 2 after DOCA induction compared to blood pres-
sure elevation only after day 4, suggesting damage by neuro-
humoral factors occurs earlier in this model [41]. Catecho-
lamine storage and metabolism were the topics for early 
studies with DOCA-salt rats [20,22]. Sympathetic neuroef-
fector transmission, specifically 2-adrenoceptors, was im-
paired in mesenteric arteries of DOCA-salt rats, where 
noradrenaline is the predominant vasoconstrictor [62]. Endo-
thelial NO synthase (eNOS) expression and activity were 
down-regulated while ACE and AT1 receptor expression 
were up-regulated in the left ventricle of DOCA-salt rats 
[63] suggesting that the local renin-angiotensin and NO sys-
tems may be unfavourably modulated in this model of hyper-
tension. Taken together, these findings suggest that, apart 
from haemodynamic factors, humoral factors also contribute 
to the cardiovascular remodelling observed in DOCA-salt 
rats.  
  Activation of the mineralocorticoid receptor is also asso-
ciated with an increased central sympathetic drive with in-
creased release of vasopressin in rats [47]. Schenk & 
McNeill [64] argue that the sodium retention in DOCA-salt 
rats alters central neurohormonal pressor baroreflexes, in-
cluding increased sympathetic nerve activity, baroreflex at-
tenuation and the activation of the brain renin-angiotensin 
system. Sodium channels or exchangers may be involved in 
the central responses to DOCA-salt treatment since amilo-
ride and its analogue, benzamil, attenuated hypertension 
when given centrally but not peripherally [65].  
PHARMACOLOGICAL EVIDENCE THAT DOCA-
SALT RATS ARE A MODEL OF OXIDATIVE AND 
INFLAMMATORY STRESS 
  Another approach to determining whether the DOCA-salt 
hypertensive rat is an appropriate model for oxidative stress 
in the cardiovascular system is to determine organ responses 
to compounds that alter reactive oxygen species concentra-
tions, especially superoxide. If different compounds either 
decrease superoxide concentrations or increase removal of 
superoxide by independent mechanisms, but all reduce car-
diovascular symptoms, then this strongly suggests that con-
trol of superoxide concentrations is the mechanism for the 
improvement of cardiovascular function. This hypothesis has 
been tested using the compounds and mechanisms outlined 
in Fig. (1).  
  Using this hypothesis, inhibition of enzyme systems that 
produce superoxide should improve cardiovascular structure 
and function in DOCA-salt rats. Small molecules that inhibit 
NADPH oxidase [49, 66] should also decrease cardiovascu-
lar responses in DOCA-salt hypertensive rats. Apocynin 
(acetovanillone) inhibits the assembly of NADPH oxidase 
and therefore enzyme activity; it decreased superoxide pro-
duction in aortic rings from DOCA-salt rats while chronic 
administration for 28 days decreased systolic blood pressure 
[67]. In DOCA-salt rats, the sesame lignan, sesamin, de-
creased NADPH oxidase subunit expression, prevented the 
increased NADPH oxidase activity, decreased aortic super-
oxide production and lowered blood pressure [68]. Both 
NADPH oxidase and xanthine oxidase contributed to vascu-
lar superoxide production in DOCA-salt rats; both apocynin 
and allopurinol as selective inhibitors lowered blood pres-
sure [69].  
  Since superoxide production by NADPH oxidase is in-
creased by angiotensin II and endothelin by activating selec-
tive receptors, antagonism of these receptors should then 
prevent or reverse oxidative damage to the cardiovascular 
system in DOCA-salt rats. Treatment with captopril (ACE 
inhibitor) or candesartan (AT1 receptor antagonist) de-
creased collagen I mRNA and both perivascular and intersti-
tial collagen deposition in the left ventricles as well as the 
increased stiffness of the ventricle without changing systolic 
blood pressure [24]. The ETA-selective antagonist, A-
127722, reversed and prevented cardiac and vascular remod-
elling in the DOCA-salt rat [35]. Responses included at-
tenuation of the increased blood pressure and ventricular 
hypertrophy, prevention of monocyte/macrophage accumula-
tion in the left ventricle, attenuation of the increased left ven-
tricular collagen deposition, reversal of the increased ven-
tricular stiffness, decrease of the action potential duration 
prolongation and improved vascular function [35].  294    Current Cardiology Reviews, 2010, Vol. 6, No. 4  Iyer et al. 
  Rapid removal of superoxide should also improve the 
cardiovascular system in DOCA-salt rats if oxidative stress 
is important in this model. L-arginine is the biological pre-
cursor of NO; NO removes superoxide by a very rapid reac-
tion to form the reactive peroxynitrite radical, ONOO
.. 
Chronic administration of L-arginine to DOCA-salt rats 
markedly decreased the structural changes in the heart and 
improved both cardiac and vascular function suggesting that 
rapid removal of superoxide is beneficial [34]. Increased 
ONOO
. can nitrate tyrosine resides in two collagen fibres to 
increase collagen cross-linking and affect cardiovascular 
function [70]. Aminoguanidine, an inhibitor of collagen 
crosslinking, prevented these changes in cardiovascular 
structure and function in the DOCA-salt rats [32]. Superox-
ide dismutase is the physiological regulator of superoxide 
removal; acute administration of superoxide dismutase did 
not change blood pressure in DOCA-salt rats [71]. There are 
no long-term studies with increased superoxide dismutase to 
investigate changes in cardiovascular structure or function in 
DOCA-salt rats. Acute treatment with the superoxide dismu-
tase-mimetic, tempol, did not lower vascular superoxide 
concentrations but lowered blood pressure by direct inhibi-
tion of sympathetic nerve activity [71].  
  Activation of enzymes that remove superoxide or its 
product, hydrogen peroxide, should also decrease cardiovas-
cular damage in DOCA-salt rats. Selenium is an essential 
trace element as part of selenoproteins such as glutathione 
peroxidase and thioredoxin reductase that are important in 
removing hydrogen peroxide produced by superoxide dismu-
tase [72]. Thus, an increased dietary selenium intake may 
offer cardioprotection against oxidative stress, for example 
in adriamycin-induced damage [73]. In DOCA-salt rats, se-
lenium supplementation reduced collagen deposition and 
passive diastolic stiffness of the left ventricle, suggesting 
that this intervention indirectly reduces superoxide concen-
trations in the heart (Adams and Brown, unpublished re-
sults).  
  Naturally occurring compounds with antioxidant actions 
in vivo acting via different mechanisms should all improve 
cardiovascular function in DOCA-salt rats if oxidative spe-
cies are the key mediators of damage. Resveratrol is an ef-
fective antioxidant in vivo by increasing NO synthesis and 
also maintaining the reduced intracellular redox state via the 
thioredoxin system [74]. Studies on animal models of human 
disease suggest that resveratrol has the potential to decrease 
cardiovascular symptoms in patients with myocardial infarc-
tion, arrhythmias, hypertension, cardiomyopathies, fibrosis, 
atherosclerosis, thrombosis and diabetes [74]. In DOCA-salt 
rats, resveratrol decreased blood pressure, improved cardiac 
structure and function and improved endothelial-dependent 
responses to acetylcholine in isolated blood vessels (Chan, 
Iyer and Brown, unpublished results). Resveratrol may also 
induce heme oxygenase-1; induction of heme oxygenase-1 
with hemin lowered blood pressure, reduced markers of oxi-
dative stress and inflammation and improved renal structure 
and function in DOCA-salt rats [75].  
  Many other naturally occurring antioxidants are known, 
including vitamin E (tocopherol), vitamin C (ascorbic acid) 
and  -lipoic acid. The increased blood pressure and renal 
damage was ameliorated by treatment of DOCA-salt rats 
with either vitamin E or C [76]. Treatment of DOCA-salt 
rats with -lipoic acid may suppress renal and vascular en-
dothelin overproduction, leading to decreased blood pressure 
and both renal and vascular protection [77]. In the heart, L-
carnitine attenuated remodelling and improved function in 
DOCA-salt rats, possibly by decreasing the production of 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Mechanisms and compounds to decrease formation or increase removal of superoxide. 
ET-1, endothelin-1; ANGII, angiotensin II; NOS, NO synthase; HO-1, heme oxygenase-1; SOD, superoxide dismutase; GPx, glutathione 
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excess reactive oxygen species by the mitochondrial respira-
tory chain [28]. 
  Similar arguments using compounds that inhibit inflam-
mation at different targets can be used to show that the 
DOCA-salt rat is a model of inflammation-induced damage 
in the cardiovascular system. This will particularly apply to 
the development of fibrosis since this process is initiated by 
infiltration of inflammatory cells into the myocardium. Inhi-
bition of infiltration, for example with fasudil [78] or tra-
nilast [79], attenuated cardiac fibrosis in DOCA-salt rats. 
Activation of inflammatory cells within the myocardium will 
produce inflammatory mediators such as the cyclo-
oxygenase products of arachidonic acid; aspirin prevented 
angiotensin II-induced hypertension and oxidative stress 
[80]. Similar experiments with cyclo-oxygenase inhibitors in 
DOCA-salt rats have not been reported. However, treatment 
with a fermented wheat germ extract, Avemar, which inhib-
its cyclo-oxygenase activity, decreased macrophage infiltra-
tion resulting in decreased collagen deposition in the ven-
tricular myocardium, reversed an increased stiffness of the 
left ventricle and improved cardiac function in DOCA-salt 
hearts [29]. The complement system is a primary mediator of 
the inflammatory process with complement factor 5a (C5a) 
showing potent chemotactic activity. Prevention of the infil-
tration of inflammatory by selective inhibition of this activity 
[81] is a potential mechanism to decrease fibrosis in the 
DOCA-salt rat heart.  
  Control of the inflammatory process by controlling the 
degree of acetylation of nuclear histone and non-histone pro-
teins can be achieved by inhibitors of histone (lysine) deace-
tylases (HDACs or KDACs). Compounds such as the anti-
cancer drug, suberoylanilide hydroxamic acid (SAHA), pre-
vent pro-inflammatory cytokine production with therapeutic 
effects reported in animal models of inflammatory diseases 
[82]. Treatment of DOCA-salt rats with SAHA attenuated 
cardiovascular remodelling, especially fibrosis, and im-
proved cardiovascular function [27].  
  The nuclear factor B (NFB) pathway is pivotal in the 
production of inflammatory mediators, so control of this 
pathway should decrease fibrosis and improve function in 
DOCA-salt rat hearts. Fenofibrate, an activator of PPAR-, 
suppressed inflammatory gene expression associated with 
NFB, prevented myocardial fibrosis and improved cardiac 
function in DOCA-salt rats [83]. Rosiglitazone as a PPAR- 
agonist inhibited the expression of TGF and cyclo-
oxygenase-2 in the kidney of DOCA-salt rats; this was asso-
ciated with decreased blood pressure and the prevention of 
renal injury, especially tubular injury and glomerulosclero-
sis, in these rats [84]. Renal injury in DOCA-salt rats was 
decreased by inhibition of the inflammatory cytokine, TNF, 
with etanercept [85]. Similar studies on cardiac damage in 
DOCA-salt rats are yet to be reported.  
  Compounds with pleiotropic anti-inflammatory responses 
should also decrease cardiac fibrosis and improve cardiac 
function in DOCA-salt rats. The combined ACE and 
vasopeptidase inhibitor, omapatrilat, attenuated the devel-
opment of cardiovascular hypertrophy, inflammation, fibro-
sis, and ventricular action potential prolongation in DOCA-
salt rats [36]. The lipid-lowering HMGCoA reductase inhibi-
tor, rosuvastatin, also attenuated the development of cardio-
vascular hypertrophy, inflammation, fibrosis and ventricular 
action potential prolongation in DOCA-salt rats [31]. Pir-
fenidone, an effective compound against lung inflammation, 
attenuated cardiac fibrosis and decreased cardiac stiffness 
without lowering blood pressure in DOCA-salt rats [37].  
CONCLUSIONS  
  The DOCA-salt model rapidly induces cardiovascular 
remodelling as in chronic hypertension in humans. Interven-
tions that reduce the concentrations of reactive free radicals 
such as superoxide, either by decreasing production or in-
creasing removal, decrease the remodelling in the DOCA-
salt heart and vasculature. Compounds that suppress the in-
flammatory responses also decrease remodelling, especially 
fibrosis. Thus, this model emphasises the role of both reac-
tive free radicals and inflammation in the development of 
cardiovascular remodelling. The DOCA-salt rat provides a 
suitable model to allow the testing of natural and synthetic 
compounds with anti-oxidant or anti-inflammatory responses 
for their effects on cardiovascular remodelling. This provides 
opportunities for the development of new therapeutic agents 
for chronic cardiovascular disease.  
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